Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma

Table 4 Comparison of differences in prognostic indicators between drug groups

Characteristics	No CCB/aspirin, n (%)	CCB and aspirin, n (%)	Aspirin without CCB, n (%)	CCB without Aspirin, n (%)	P value
	n = 98	n = 15	n = 40	n = 11
Sex
Male	56 (57.1)	5 (33.3)	25 (62.5)	8 (72.7)	0.169
Age (yr)
< 60	39 (39.8)	5 (33.3)	8 (20.0)	3 (27.3)	0.157
≥ 60	59 (60.2)	10 (66.7)	32 (80.0)	8 (72.7)
Blood pressure status
Hypertensive	27 (27.6)	13 (86.7)	22 (55.0)	11 (100.0)	0.000
Non-hypertensive	71 (72.4)	2 (13.3)	18 (45.0)	0 (0.0)
BMI
< 18.5	2 (2.0)	0 (0)	1 (2.5)	0 (0.0)	0.307
18.5-25	52 (53.1)	5 (33.3)	24 (60.0)	3 (27.3)
> 25	41 (41.8)	9 (60.0)	14 (35.0)	8 (72.7)
Adjuvant chemotherapy
Received post-op	69 (70.4)	9 (60.0)	23 (57.5)	9 (81.8)	0.333
Not received	24 (24.5)	5 (33.3)	13 (32.5)	1 (9.1)
CA19-9
< 47	27 (27.6)	3 (20.0)	9 (22.5)	1 (9.1)	0.437
47-1000	51 (52.0)	7 (46.7)	20 (50.0)	7 (63.6)
> 1000	8 (8.2)	3 (20.0)	6 (15.0)	3 (27.3)
ASA grade
1-2	81 (82.7)	12 (80.0)	22 (55.0)	8 (72.7)	0.008
3-4	17 (17.3)	3 (20.0)	18 (45.0)	3 (27.3)
Resection value
R0	14 (14.3)	6 (40.0)	9 (22.5)	5 (45.5)	0.020
R1	83 (84.7)	9 (60.0)	31 (77.5)	6 (54.5)
T status
T1-2	3 (3.1)	2 (13.3)	1 (2.5)	0 (0.0)	0.199
T3-4	95 (96.9)	13 (86.7)	39 (97.5)	11 (100.0)
N status
N0	7 (7.1)	3 (20.0)	5 (12.5)	0 (0.0)	0.242
N1	90 (91.8)	12 (80)	35 (87.5)	11 (100.0)

P-values were calculated using tests χ² tests. CCB: Calcium channel blockers; ASA: American society of anaesthesiologists; BMI: Body mass index.